Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + thiotepa
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Zanubrutinib + thiotepa is an investigational combination regimen consisting of zanubrutinib, a second-generation small molecule Bruton's tyrosine kinase (BTK) inhibitor, and thiotepa, an alkylating agent. Zanubrutinib selectively inhibits BTK, a key enzyme in the B-cell receptor signaling pathway that promotes survival and proliferation of malignant B cells. Thiotepa is a cytotoxic chemotherapy agent that cross-links DNA strands to induce cell death and has high central nervous system (CNS) penetration. This combination is being studied primarily for the treatment of primary CNS lymphoma (PCNSL), aiming to improve remission rates by combining targeted therapy with cytotoxic chemotherapy[2][1]. The regimen may be used as induction or consolidation therapy, including in patients undergoing autologous stem cell transplantation with thiotepa-based conditioning[2][4].
- Brand names
- Brukinsa (zanubrutinib)Tepylute (thiotepa)
02
Targets
BTK (Bruton tyrosine kinase)DNA interstrand cross-link
Beyond the preview
Go deeper on zanubrutinib + thiotepa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + thiotepa.